Is the methyltransferase, ASH1L a therapeutic target for endocrine-related cancers?
Is the methyltransferase, ASH1L a therapeutic target for endocrine-related cancers?
批准号:
2594271
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
One of the features of aging is the loss of sex hormones and in-turn the change in function of androgen and oestrogen nuclear receptors. Changes in the epigenetic co-regulators of the nuclear receptors during aging are known to play a role in many of the age-related diseases such as dementia, diabetes and cancer. Alternative splicing is a mechanism crucial for proteomic diversity. Recent advancements in the understanding of histone modifications (epigenetic) and RNA methylation (epitranscriptomic) role in alternative splicing regulation, not only in transcriptional and translational regulation has highlighted the need for continued progress in dissecting this complex process. Recently, histone modifications have been identified as guiding the RNA methyltransferase complex to nascent RNA molecules allowing m6A addition co-transcriptionally. This exciting study linked epigenetics playing crucial role in RNA methylation. Further understanding of factors that can influence the epigenetic changes that will lead to changes in RNA methylation in disease needs to be investigated. Additionally, the androgen receptor was shown to play a role in alternative splicing in the presence of androgen. Therefore, this project will investigate how histone modifications influence nuclear receptor transcriptional and alternative splicing regulation utilising prostate and breast cancer cell models. Techniques that will be utilised are RNA inteference, analysis of RNAseq and ATACseq data, cell culture, qPCR, protein detection (immunoblotting and immunohistochemistry), pharmacological inhibitors, phenotypic assays (proliferation, invasion, apoptosis).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
RIP2通过ASH1L /KEAP1/Nrf2通路介导直肠癌放疗抵抗的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
ASH1L介导肝癌细胞与肝星状细胞协同促进肝癌发生发展的作用及机制研究
-
批准号:82372768
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:李妍
-
依托单位:
抽动秽语综合征易感基因ASH1L突变遗传学及其介导纹状体直接与间接通路调控失衡的致病机制研究
-
批准号:82371546
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:刘世国
-
依托单位:
外周血ASH1L和PFAS m6A修饰作为胃癌新型生物标志物的临床价值及分子机制研究
-
批准号:82102494
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:葛李晨
-
依托单位:
组蛋白甲基转移酶Ash1l通过调节Stac2基因表达影响破骨分化的作用及机制研究
-
批准号:82100945
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:赵晓丽
-
依托单位:
Tourette综合征新易感基因ASH1L遗传学验证及其突变影响多巴胺代谢异常的机制研究
-
批准号:82001441
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:刘文淼
-
依托单位:
Ash1L调控NK细胞组蛋白H3K4甲基化水平在SAA免疫发病机制中的作用
-
批准号:81970115
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:付蓉
-
依托单位:
ASH1L基因参与的神经发育与功能疾病机制研究
-
批准号:31970903
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:管吉松
-
依托单位:
ASH1L在HIV-1潜伏储存库形成和再激活中的作用及机制研究
-
批准号:81802008
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:刘金彪
-
依托单位:
H3K4甲基化转移酶Ash1l在免疫应答调控中的作用及机制研究
-
批准号:81671546
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2016
-
负责人:刘娟
-
依托单位: